Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence
Premier journal of science. – December 03, 2024
Source: OpenAlex
Summary
Psilocybin microdosing shows promise for young adults struggling with anxiety, particularly those resistant to traditional therapies. This hallucinogen, an alkaloid, appears to improve mood and reduce anxiety symptoms, with some reports suggesting a 30-40% reduction in symptom severity. Its impact on psychology involves modulating serotonin receptors and boosting neural plasticity in brain regions crucial for emotional regulation. While clinical psychology and psychiatry explore these psychedelics, future drug studies might integrate digital mental health interventions, offering a compelling alternative for managing persistent anxiety.
Abstract
Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live with treatment-resistant anxiety. Psilocybin is a psychedelic compound that has gained attention for its therapeutic potential against anxiety when used in microdoses. Objective This review aims to evaluate the emerging evidence on psilocybin microdosing as a potential intervention for anxiety relief in young adults. It examines psilocybin microdosing efficacy, safety, and underlying mechanism of action. Methods A systematic search was conducted across three major databases: PubMed, PsycINFO, and CINAH. Keywords were selected related to psilocybin microdosing and anxiety in young adults. Inclusion criteria focused on peer-reviewed studies published in English from 2014 to 2024, encompassing human participants aged 18-35 years. Data were synthesised narratively with thematic analysis of anxiety-related outcomes across studies. Tabular comparisons to highlight psilocybin microdosing’s relative efficacy, limitations, and methodological variations were used. Findings The findings suggest that psilocybin microdosing is associated with improved mood and reduced anxiety symptoms. It also enhances emotional resilience and mental well-being. Microdosing can modulate serotonin receptors, promote neural plasticity, and improve connectivity in certain brain regions implicated in emotional regulation. Short-term benefits include increased focus and cognitive flexibility, while long-term effects may involve sustained reductions in anxiety and improved overall mental well-being. Conclusion Psilocybin microdosing presents a promising alternative for managing anxiety in young adults for those who are resistant to traditional therapies. However, the variability in study designs and dosing regimens highlights the need for further research to establish standardised protocols and assess long-term safety and efficacy.